
An IBD reseacher seeking truth,a doctor seeking hope. Gastroenterologist with focus on #IBD, especially intestinal stricture.
Cleveland Heights, OH
Joined August 2019
- Tweets756
- Following342
- Followers606
- Likes996
Ren Mao,MD,PhD retweeted
🎤 Spoke on emerging endoscopic interventions at #AIDDS2026, Asan, Seoul.
A focused, high-level IBD meeting spanning AI, dysplasia, fibrosis, creeping fat and interventional endoscopy—with stimulating discussions across disciplines! 🇰🇷
Grateful to Asan IBD’s Prof @BDYE_IBD , Prof @sang_hyoung , Prof Dong-Hoon Yang & Prof Sung Wook Hwang for the warm hospitality, and to @IBD_Sir , Prof Yasuharu Maeda & fellow Korean speakers for the excellent scientific exchanges! 🙏
#AIDDS2026 #IBD
Ren Mao,MD,PhD retweeted
Three long-acting antibodies. One at a time.
That was SKYLINE Part A, presented by Silvio Danese at UEG Week this afternoon. Spyre's SPY001 (α4β7), SPY002 (TL1A) and SPY003 (IL-23) are engineered to last, with half-lives of 75 to 85 days. The plan is subcutaneous maintenance every three to six months.
Open-label. Week 12. About 45 patients per arm. Clinical remission 40%, 33% and 20%. Histology (primary endpoint) improved by around 60% in every arm. No drug-related serious adverse events.
The headline numbers were already out (press release). Today they sat side by side, and that is where it gets interesting.
My read. Each one works. SPY001 looks strongest, but 81% of its patients were treatment-naive. SPY002 sits where the TL1A class sits. SPY003 came in below where IL-23 drugs usually land in similar patients.
And there is no placebo ... which is also good. But open-label numbers flatter.
The real test is Part B. Placebo-controlled, three combinations, readout in 2027. J&J's DUET-UC has already shown how hard it is for two drugs to clearly beat one.
Single targets got us here. Combinations have to earn their place.
@my_ueg @spyretx @silvio_silvio75
Time to reflect and celebrate #VERDICT
With those who were instrumental in conceiving (@PeyrinBiroulet ) and delivering (@vipuljairath )
Fitting tribute to #ProfFeagan
Thanks to all the patients who participated in this practice changing study
Ren Mao,MD,PhD retweeted
One of a kind anti-fibrotic, Ontunisertib. Results from OLE presented by @IBD_FloMD.
➡️ Well tolerated, no safety concerns
➡️No stricture progression on MRE
➡️3% EBD/✂️; only 1 EBD/48 weeks
@AnjaMD_IBD @JordiRimola @RPanaccione @BettenworthDb #STARconsortium
#UEGWeek @my_ueg
Ren Mao,MD,PhD retweeted
Thank you @KR_Foundation for including me. This is an inspiring conference. We are grateful for you supporting the #IBD community. @ManuelBragaMD @JosephHabibi_MD @HolubarStefan @AnthonydeBuck
Dr. Florian Rieder @IBD_FloMD of the Florian Rieder Laboratory at @CCLRI, is presenting on cracking the nut of stricturing Crohn’s disease. #InnovationsSymposium2026
Explore his research into new ways to treat IBD patients with established strictures: lerner.ccf.org/inflammation-…
Ren Mao,MD,PhD retweeted
1/When we diagnose IBD, we don't know which therapy will work for that patient. Could the biopsies we already take give us clues?
Presenting a valuable intestinal cell atlas: doi.org/10.1172/JCI202488
@MikeKattahMD, @alexis_combes & team @UCSFMedicine applied spatial gene mapping to archived colitis biopsies, identifying immune cell neighborhoods that explain why some patients are resistant to vedolizumab and others respond well.
@MayoClinic
#Colitis #IBD
Ren Mao,MD,PhD retweeted
🚨Hot off the press: updated #ECCO GL on medical and surgical treatment of #ulcerativecolitis
The update addresses new therapies, rescue strategies, treat-to-target care and the evolving role of surgery @Y_ECCO_IBD @IBD_FloMD @DignassAxel @RajaAtreya
Ren Mao,MD,PhD retweeted
We are delighted today to hear Dr Florian Rieder discuss stricturing Crohn’s disease! @IBD_FloMD @MayoClinicGIHep @clevelandclinic flagellin stimulates fibroblasts
Ren Mao,MD,PhD retweeted
📣 New episode out for #IBDEssentials: @RPanaccione discusses recent clinical trial results informing clinical decision making youtu.be/NE0BYpuMI60?si=steX… via @YouTube - check it out… @CathyLuMD @DignassAxel @DCharabaty
Ren Mao,MD,PhD retweeted
🔬#STARConsortium Industry Meeting at #DDW2026🔬29 corporate partners, investors, regulatory experts and interdisciplinary clinical scientists all in for one mission: Building a pathway to testing anti-stricture therapies in Crohn’s disease. #SmallEgoBigResults @MRegueiroMD
Welcome back to Guangzhou ASAP, 😄
Just wrapped up an incredible #DDW2026! Thrilled to have shared our team's latest research on the premier stage for gastroenterology. A massive year for us: 1 Late-Breaking Abstract + 3 Oral Presentations! 🎉 Excited to share the highlights 👇
2
158
Ren Mao,MD,PhD retweeted
Time-trajectory analyses reveals evolution of serum Proteome during the preclinical phase in CD @RirongChen @DDWMeeting
#PROMISEConsortium @KenCroitoru @JeanFredericCo1 @khalili_MD #IngaPeter @TurpinWilliams @ryanungaro #EmilyLopes #FrancescaPetralia #BijuBharali
@The_GEMProject
Great Rirong
Childhood Exposure to Sibling with CD associated with Increased risk of CD and Altered Microbial Signatures @DDWMeeting
@RirongChen @TurpinWilliams @KenCroitoru @The_GEMProject @SinaiHealth @guthealthmd @annegri50789035
1
1
140
Ren Mao,MD,PhD retweeted
CyTOF Immunophenotyping data in the Pre-disease Phase of CD @BHUPESHTHAKUR30 @DDWMeeting
@KenCroitoru @The_GEMProject @TurpinWilliams #BijuBharali @guthealthmd @RirongChen @SinaiHealth @ImmunologyUofT
congrats.
Preclinical disease and Primary prevention of IBD: Where do we stand?
@KenCroitoru @DDWMeeting
@The_GEMProject @TurpinWilliams @BHUPESHTHAKUR30 @RirongChen
@guthealthmd @annegri50789035 @JeanFredericCo1 @khalili_MD @ryanungaro @pedsIBDdoc
1
98
Ren Mao,MD,PhD retweeted
Replying to @DDWMeeting
amazing steps
Fibrostenotic #Crohns disease is entering a new phase of clinical development🔬
At the #STAR Consortium Industry Meeting during #DDW it was inspiring to see progress in PRO tools, biomarkers, trial frameworks, and potential anti-fibrotic therapies #FlorianRieder #IBD
Ren Mao,MD,PhD retweeted
#DDW2026 first IBD session. Registration a farce. No way into the room. Massive huddle outside a tiny tv screen. My advice is take advantage of the sunny morning and watch online. Frustrating start to the day!!!
Novak Just visited us last week😀
Completed my three week Research & IBUS training visit to Calgary today! Many, many thanks to the greats here in this city by the Rockies.
First of all, my greatest gratitude goes to @gilkaplan who provided so many opportunities to learn and collaborate, as well as supporting me in every ways so I could get the best out of this. Thank you so much.
And @novakkerri , who was so supportive during my IBUS module 2 training and who I became to admire ever more, I'll always remember the encouragements you gave.
@CathyLuMD I learned so much! And it was so fun doing IUS with you :)
And I met the revered @RPanaccione here in person. His sincere advices on leadership was so memorable. I hope I could live up to what I've said and discussed here.
@SeowCynthia it was so nice meeting you here. Really. Just hoping you get some rest after such busy days.
And all the good friends I've made here. Shinji, Abel, Eduard, Joey, Stephanie, Lindsay, Julia, Alia, Larissa, Richard, Ro, and there's so many I would like to thank..
Now I'm heading to Chicago to attend DDW. What wonderful days these have been. I'm ever so grateful.
#IBD #IBUS #Calgary
1
133







































































